Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Revenue (2016 - 2025)

KalVista Pharmaceuticals' Revenue history spans 7 years, with the latest figure at $3.8 million for Q2 2020.

  • On a quarterly basis, Revenue rose 30.69% to $3.8 million in Q2 2020 year-over-year; TTM through Jul 2024 was $9.3 million, a N/A change, with the full-year FY2025 number at $11.0 million, down 78.0% from a year prior.
  • Revenue hit $3.8 million in Q2 2020 for KalVista Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over the last five years, Revenue for KALV hit a ceiling of $5.6 million in Q4 2018 and a floor of $7000.0 in Q1 2016.
  • Historically, Revenue has averaged $2.3 million across 5 years, with a median of $2.3 million in 2018.
  • Biggest five-year swings in Revenue: tumbled 90.15% in 2017 and later soared 4145.61% in 2018.
  • Tracing KALV's Revenue over 5 years: stood at $197000.0 in 2016, then skyrocketed by 472.08% to $1.1 million in 2017, then soared by 396.18% to $5.6 million in 2018, then fell by 29.9% to $3.9 million in 2019, then decreased by 2.45% to $3.8 million in 2020.
  • Business Quant data shows Revenue for KALV at $3.8 million in Q2 2020, $1.6 million in Q1 2020, and $3.9 million in Q4 2019.